Engineered liposomes targeting hepatic stellate cells overcome pathological barriers and reverse liver fibrosis

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 368, P. 219 - 232

Published: Feb. 28, 2024

Language: Английский

---

The evidence-based multifaceted roles of hepatic stellate cells in liver diseases: A concise review

Life Sciences, Journal Year: 2024, Volume and Issue: 344, P. 122547 - 122547

Published: March 7, 2024

Language: Английский

---

Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(2), P. 189086 - 189086

Published: Feb. 9, 2024

Language: Английский

---

The impact of, and expectations for, lipid nanoparticle technology: From cellular targeting to organelle targeting

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 516 - 527

Published: May 9, 2024

Language: Английский

---

Nanoparticle: Pathogenesis, Innovative Diagnosis, and Therapy of Liver Fibrosis

ChemistrySelect, Journal Year: 2025, Volume and Issue: 10(7)

Published: Feb. 1, 2025

Abstract Liver fibrosis, a progressive condition resulting from chronic liver injury, can lead to cirrhosis and hepatocellular carcinoma. Nanoparticles have emerged as promising tools for their diagnosis treatment due unique properties. This review highlights advances in lipid‐based (e.g., liposomes, solid lipid nanoparticles), polymer‐based nanocapsules, dendrimers), inorganic iron oxide, gold biological nanoparticles extracellular vesicles, exosomes). These enhance imaging contrast MRI CT, enabling non‐invasive fibrosis detection, deliver drugs or gene‐editing hepatic stellate cells (HSCs) targeted therapy. Extracellular vesicles (EVs) exosomes also show potential biomarkers therapeutic carriers. However, challenges such limited targeting efficiency, toxicity, difficulties clinical translation remain. Future research should focus on optimizing nanoparticle design, improving biocompatibility, addressing regulatory issues facilitate application. Nanoparticle‐based strategies hold great promise revolutionizing management.

Language: Английский

---

Molecular mechanisms of lncRNA NEAT1 in the pathogenesis of liver-related diseases, with special focus on therapeutic approaches

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 269, P. 155867 - 155867

Published: Feb. 26, 2025

Language: Английский

---

Harnessing the composition of lipid nanoparticles to selectively deliver mRNA to splenic immune cells for anticancer vaccination

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: March 7, 2025

Language: Английский

---

MCT4 Knockdown by Tumor Microenvironment-Responsive Nanoparticles Remodels the Cytokine Profile and Eradicates Aggressive Breast Cancer Cells

Colloids and Surfaces B Biointerfaces, Journal Year: 2024, Volume and Issue: 238, P. 113930 - 113930

Published: April 25, 2024

Language: Английский

---

Hepatic stellate cell-targeted chemo-gene therapy for liver fibrosis using fluorinated peptide-lipid hybrid nanoparticles

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 376, P. 601 - 617

Published: Oct. 25, 2024

Language: Английский

---

Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer

AAPS PharmSciTech, Journal Year: 2024, Volume and Issue: 25(1)

Published: Jan. 24, 2024

Language: Английский

---